Browsing: Clash

Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments. 

Novo NordiskNVO and Eli LillyLLY lead the diabetes and obesity market, driven by their blockbuster GLP-1 therapies. Lilly sells its dual GIP/GLP-1 agonist tirzepatide as Mounjaro for type II diabetes and as Zepbound for obesity. Novo Nordisk markets semaglutide as Ozempic and Rybelsus for type II diabetes, and as Wegovy for weight management